Meta-Analysis Evaluates the Efficacy and Safety of Rituximab for Primary Sjögren's Syndrome
Primary Sjögren's syndrome is a chronic autoimmune disease that primarily attacks the glands responsible for producing moisture throughout the body. Most people know it as the condition behind relentless dry eyes and dry mouth, but its reach extends much further, touching the joints, lungs, kidneys, nervous system, and skin. It affects roughly one in four hundred people, with women diagnosed significantly more often than men, and it carries a unique and frustrating burden: there are currently no approved therapies that specifically target the underlying disease process. Patients and their doctors often find themselves navigating treatment with little formal guidance.
Because Sjögren's syndrome is driven in large part by the overactivation of B-cells, the immune cells that produce antibodies, researchers have long been drawn to rituximab as a potential treatment. Rituximab is a monoclonal antibody that works by depleting B-cells through their CD20 surface marker. It has been FDA-approved for other autoimmune conditions including rheumatoid arthritis and certain types of vasculitis, and for years has been used off-label in Sjögren's for patients with significant systemic involvement, including vasculitis, peripheral neuropathy, and severe inflammatory fatigue.
A meta-analysis published in Frontiers in Immunology in June 2025 set out to provide a comprehensive and systematic evaluation of rituximab's evidence base. The research team, led by Xiao Zheng and colleagues at Hebei Provincial People's Hospital in China, searched major medical databases to identify clinical trials and controlled studies of rituximab in primary Sjögren's syndrome. Their objective was to methodically assess both how well the drug works and how safe it is across a wide range of patients.
Meta-analyses play a particularly important role when individual clinical trials have produced inconsistent or conflicting results. Studies of rituximab in Sjögren's have varied in their findings depending on patient selection, dosing protocols, and outcome measures used. By pooling results, a well-designed meta-analysis can identify consistent trends and provide more reliable estimates of treatment effects. For Sjögren's patients and their rheumatologists, this kind of synthesized evidence helps answer the practical question: for which patients, and in which situations, does rituximab offer meaningful benefit?
The existing literature suggests that rituximab tends to show greater benefit in controlling systemic disease manifestations than in reversing the hallmark glandular symptoms of dryness. Measures of overall disease activity, such as the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), have improved in multiple controlled studies. Patients with active systemic disease, particularly those with vasculitis, cryoglobulinemia, or severe fatigue driven by systemic inflammation, appear to be the best candidates. Glandular function measures, such as stimulated salivary flow, have shown less consistent improvement.
Safety outcomes are equally important when evaluating rituximab. The drug carries risks that include infusion reactions, increased susceptibility to infections, and in rare cases, more serious complications. The meta-analysis examined adverse event rates alongside efficacy data, offering a balanced view that clinicians need before recommending this treatment. For patients considering rituximab, this research provides context for an honest conversation about benefits and risks. As newer targeted therapies move through regulatory review, having a clear picture of what existing off-label options offer remains essential to the treatment decision.
Source: Frontiers in Immunology, June 24, 2025. Zheng X, Di J, Chen X, et al. This summary is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for guidance specific to your situation.